CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies. Seminars in Hematology
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies. Seminars in Hematology
The last decade has seen the monoclonal antibody (mAb), rituximab, transform clinical management of many non-Hodgkin lymphomas and more recently provide new opportunities for controlling autoimmune conditions, such as rheumatoid arthritis. Although not yet fully determined, the explanation for this success appears to lie with the inherent properties of its target, CD20, which allow rituximab to recruit potent cytotoxic effectors with unusual efficiency. In this review we detail the properties of CD20 that make it such an effective therapeutic target and describe how different mAbs change the membrane distribution and internalization of CD20 and have distinct modes of cytotoxic activity.
107-114
Beers, Stephen A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Chan, H.T. Claude
b109c93f-7e9a-44ee-ad12-da757b1b11fc
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
April 2010
Beers, Stephen A.
a02548be-3ffd-41ab-9db8-d6e8c3b499a2
Chan, H.T. Claude
b109c93f-7e9a-44ee-ad12-da757b1b11fc
French, Ruth R.
a95ea7a1-7aeb-4c20-998e-fde663613fd1
Cragg, Mark S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Glennie, Martin J.
9f6f0eff-4560-48c2-80cd-0ec116110ded
Beers, Stephen A., Chan, H.T. Claude, French, Ruth R., Cragg, Mark S. and Glennie, Martin J.
(2010)
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies. Seminars in Hematology.
Seminars in Hematology, 47 (2), .
(doi:10.1053/j.seminhematol.2010.01.001).
Abstract
The last decade has seen the monoclonal antibody (mAb), rituximab, transform clinical management of many non-Hodgkin lymphomas and more recently provide new opportunities for controlling autoimmune conditions, such as rheumatoid arthritis. Although not yet fully determined, the explanation for this success appears to lie with the inherent properties of its target, CD20, which allow rituximab to recruit potent cytotoxic effectors with unusual efficiency. In this review we detail the properties of CD20 that make it such an effective therapeutic target and describe how different mAbs change the membrane distribution and internalization of CD20 and have distinct modes of cytotoxic activity.
This record has no associated files available for download.
More information
Published date: April 2010
Identifiers
Local EPrints ID: 148173
URI: http://eprints.soton.ac.uk/id/eprint/148173
ISSN: 0037-1963
PURE UUID: 233764b4-fa50-4cb2-a03d-2ab89ef5e637
Catalogue record
Date deposited: 27 Apr 2010 13:48
Last modified: 14 Mar 2024 02:45
Export record
Altmetrics
Contributors
Author:
H.T. Claude Chan
Author:
Ruth R. French
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics